
How we made ARDS risk readable at a glance for ICU clinicians
Bayer was building ICU Angel, a risk-monitoring platform paired with a drug intervention for ARDS. Clinicians and principal investigators needed to follow a patient's progression and medication response without digging through screens. We designed both views and ran moderated prototype testing across the whole workflow before anything was built.
Prototype tested

